GLP-1 receptor agonist
Liraglutide
An acylated GLP-1 analog with established human clinical programs and product labeling.
Why it is discussed
Established GLP-1 treatment with daily dosing products
Liraglutide is discussed as an earlier GLP-1 medicine with substantial human evidence for defined diabetes and chronic weight-management uses. It is useful educationally because it shows how indication, product, dose form, and patient population all shape an approval.
What it is
A modified version of the GLP-1 hormone.
Liraglutide is a GLP-1 receptor agonist: a peptide that activates the same cellular receptor as glucagon-like peptide-1. It is structurally similar to human GLP-1 but has modifications, including an attached fatty-acid chain, that help prolong its action. Binding to blood proteins such as albumin is one part of this design. Liraglutide and semaglutide share a receptor target but are different molecules.
How it works
Glucose-dependent signaling, appetite, and gastric emptying.
In pancreatic beta cells, GLP-1 receptor activation raises cyclic AMP, a messenger inside the cell, and promotes insulin secretion when blood glucose is elevated. Liraglutide also reduces glucagon secretion in a glucose-dependent way, helping limit glucose release from the liver.
GLP-1 signaling participates in appetite regulation and reduced food intake. Liraglutide can also delay stomach emptying, changing how quickly nutrients reach the intestine. These are related effects, not evidence of direct fat burning.
Glucose-dependent action is not a guarantee against hypoglycemia, especially with other glucose-lowering medicines. The mechanism describes the molecule; it does not establish that an online powder has the identity, delivery characteristics, or clinical evidence of an authorized product.
Scientific / evidence sources
Evidence at a glance
What is established—and what is not.
Established human clinical evidence and product labeling
Extensive human programs and product labeling establish benefits and risks for authorized liraglutide products in defined populations.
Authorization does not transfer to a differently manufactured, formulated, labeled, or supplied product.
Regulatory status
Canada and the United States are checked separately.
Authorized products exist; confirm current marketed status and indication in the Drug Product Database.
FDA-approved products exist; use the current product label for risk and indication details.
Regulatory status describes product authorization and relevant regulatory context. It is not a complete legal opinion about possession, importation, prescribing, sale, or professional practice.
If you are reviewing a product report
The molecule profile and the testing report answer different questions.
This page summarizes evidence and regulatory context. A laboratory report may address identity, purity, or quantity for one submitted sample; it does not transfer clinical evidence or product authorization.